Joanna Grudzinska-goebel PhD

Joanna Grudzinska-Goebel works as a Senior DMPK Project Lead at Bayer, focusing on Biotherapeutics and New Modalities, including mRNA/LNP-based therapies. She is the leader of the global Immunogenicity Team at Bayer, which established the Immunogenicity Risk Assessment Process for Biotherapeutics and New Modalities. As an Immunogenicity Risk Assessment Expert, she supports project teams in conducting the risk assessment. In addition, she is facilitating cross-industry alignment on Immunogenicity Risk Assessment of different modalities by leading and contributing to working groups within various industry consortia.